C. diff Risk


Oral Bioavailability


Approximate Cost



Usual Dose 1-2 gm IV q24h

Bacterial meningitis 2 gm IV q12h

CrCl >50 mL/min

  • Uncomplicated: 1 g IV Q24h

  • Meningitis: 2 g IV Q12h

  • Endocarditis & Osteomyelitis: 2 g IV Q24h

CrCl <50 mL/min

  • No change

General Information

Common Usage

Empiric therapy of bacterial meningitis

Empiric therapy of nosocomial Gram negative infections (except Pseudomonas)

Empiric therapy of hospitalized community or nursing home acquired pneumonia in combination with a macrolide

Empiric therapy of spontaneous bacterial peritonitis

Drug Monitoring


  • CBC, CMP weekly

  • Consider more frequent liver enzymes in patients with biliary disease


  • Hypersensitivity

  • Diarrhea

  • Other GI effects

  • Signs of biliary sludge

  • Signs of gallstones

Adverse Effects

  • GI effects

  • Hypersensitivity reactions

  • C. difficile

  • Biliary sludging

  • Gallstones


Antimicrobial class: Parenteral Cephalosporin - 3rd Generation

Pregnancy category: B

Average serum half life: 8 hours

Biliary penetration: Therapeutic

CSF penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Therapeutic